Chronic Myeloid Leukemia (RT-PCR) – Currently approved only for NJ BCR-ABL assay is an in vitro nucleic acid amplification test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients to monitor the response to Therapy. Indicated for Diagnosis and ongoing therapeutic monitoring. Useful for tyrosine kinase inhibitor (TKI) treatment management strategy. Lincoln Reference Laboratory BCR-ABL test offers: Turnaround time of 2-4 days. Broad coverage by most private and public insurance. Specimen Requirements Transport 5 mL whole blood […]

Chronic Myeloid Leukemia (RT-PCR) – Currently approved only for NJ
BCR-ABL assay is an in vitro nucleic acid amplification test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients to monitor the response to Therapy.

Indicated for Diagnosis and ongoing therapeutic monitoring. Useful for tyrosine kinase inhibitor (TKI) treatment management strategy.

Lincoln Reference Laboratory BCR-ABL test offers:

• Turnaround time of 2-4 days.
• Broad coverage by most private and public insurance.

Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL whole blood or 1 mL bone marrow) Specimens must be received within 48 hours of collection due to lability of RNA.

Storage/Transport Temperature – Refrigerated.

(Flow Cytometry send-out to AccuReference Lab)